Anja Schweizer

11.7k total citations · 2 hit papers
114 papers, 9.6k citations indexed

About

Anja Schweizer is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Anja Schweizer has authored 114 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 58 papers in Endocrinology, Diabetes and Metabolism, 44 papers in Molecular Biology and 31 papers in Surgery. Recurrent topics in Anja Schweizer's work include Diabetes Treatment and Management (58 papers), Pancreatic function and diabetes (27 papers) and Diabetes Management and Research (23 papers). Anja Schweizer is often cited by papers focused on Diabetes Treatment and Management (58 papers), Pancreatic function and diabetes (27 papers) and Diabetes Management and Research (23 papers). Anja Schweizer collaborates with scholars based in Switzerland, United States and Sweden. Anja Schweizer's co-authors include S. Dejager, James E. Foley, Bo Åhrén, David Mills, Jack Rohrer, Hans-Peter Hauri, Stuart Kornfeld, Michelle A. Baron, H P Hauri and R D Klausner and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Anja Schweizer

113 papers receiving 9.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Microtubule-dependent retrograde transport of proteins into the ER in the presence of brefeldin a suggests an ER recycling pathway

1990 871 citations Anja Schweizer et al. profile →
Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

2004 607 citations Bo Åhrén, Mona Landin‐Olsson et al. The Journal of Clinical Endocrinology & Metabolism profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Anja Schweizer Switzerland	53	5.2k	4.2k	2.7k	2.0k	1.7k	114	9.6k
John A. Glomset United States	50	2.3k 0.4×	6.6k 1.6×	4.5k 1.7×	1.5k 0.7×	1.2k 0.7×	85	13.3k
Susan Acton United States	22	2.3k 0.4×	3.0k 0.7×	2.6k 1.0×	536 0.3×	810 0.5×	29	8.6k
Wendy Jessup Australia	52	1.4k 0.3×	3.8k 0.9×	3.6k 1.3×	709 0.3×	1.1k 0.6×	139	8.2k
Margery A. Connelly United States	48	1.8k 0.4×	3.4k 0.8×	2.4k 0.9×	606 0.3×	1.1k 0.6×	225	7.7k
Hiroshi Ikegami Japan	44	2.5k 0.5×	2.1k 0.5×	2.8k 1.0×	477 0.2×	502 0.3×	216	6.9k
Catherine A. Reardon United States	47	903 0.2×	2.9k 0.7×	2.1k 0.8×	350 0.2×	624 0.4×	132	7.7k
Claus Hellerbrand Germany	66	1.1k 0.2×	5.7k 1.4×	1.8k 0.7×	991 0.5×	2.0k 1.1×	291	14.3k
Patricia G. Yancey United States	38	978 0.2×	2.4k 0.6×	2.5k 0.9×	516 0.3×	629 0.4×	70	5.7k
David P. Hajjar United States	47	500 0.1×	3.9k 0.9×	1.9k 0.7×	489 0.2×	595 0.3×	111	8.5k
Charalampos Aslanidis Germany	42	420 0.1×	3.6k 0.8×	1.9k 0.7×	407 0.2×	1.2k 0.7×	119	7.2k

Countries citing papers authored by Anja Schweizer

Since Specialization

Citations

This map shows the geographic impact of Anja Schweizer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anja Schweizer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anja Schweizer more than expected).

Fields of papers citing papers by Anja Schweizer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anja Schweizer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anja Schweizer. The network helps show where Anja Schweizer may publish in the future.

Co-authorship network of co-authors of Anja Schweizer

This figure shows the co-authorship network connecting the top 25 collaborators of Anja Schweizer. A scholar is included among the top collaborators of Anja Schweizer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anja Schweizer. Anja Schweizer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Tay, Wan Ting, Tiew‐Hwa Katherine Teng, Wouter Ouwerkerk, et al.. (2025). Global Patterns of Polypharmacy After Acute Heart Failure Hospitalization: Prevalence and Outcomes from the REPORT-HF Registry. European Journal of Heart Failure. 27(12). 2705–2715.

Tay, Wan Ting, Tiew‐Hwa Katherine Teng, Wouter Ouwerkerk, et al.. (2025). Quality of care delivery in patients with acute heart failure: insights from the international REPORT-HF registry. EClinicalMedicine. 80. 103031–103031. 5 indexed citations

Lee, Jingu, Anja Schweizer, Yousang Gwack, et al.. (2024). Neutrophil CRACR2A Promotes Neutrophil Recruitment in Sterile Inflammation and Ischemic Stroke. Circulation. 151(10). 696–715. 4 indexed citations

Bistola, Vasiliki, Dimitrios Farmakis, Jasper Tromp, et al.. (2024). Hospitalized Advanced Heart Failure With Preserved vs Reduced Left Ventricular Ejection Fraction. JACC Heart Failure. 13(2). 229–247. 2 indexed citations

Farmakis, Dimitrios, Jasper Tromp, Smaragdi Marinaki, et al.. (2023). Impact of Left Ventricular Ejection Fraction Phenotypes on Healthcare Resource Utilization in Hospitalized Heart Failure: A Secondary Analysis of REPORT-HF. European Journal of Heart Failure. 25(6). 818–828. 3 indexed citations

Ouwerkerk, Wouter, Jasper Tromp, John G.F. Cleland, et al.. (2022). Association of Time-to-Intravenous Furosemide with Mortality in Acute Heart Failure: Data from REPORT-HF. European Journal of Heart Failure. 25(1). 43–51. 9 indexed citations

Tromp, Jasper, John G.F. Cleland, Christiane E. Angermann, et al.. (2020). Post-discharge prognosis of patients admitted to hospital for heart failure by world region, and national level of income and income disparity (REPORT-HF): a cohort study. The Lancet Global Health. 8(3). e411–e422. 116 indexed citations

Filippatos, Gerasimos, Sadiya S. Khan, Andrew P. Ambrosy, et al.. (2015). International REgistry to Assess Medical Practice with lOngitudinal obseRvation for Treatment of Heart Failure (REPORT-HF): Rationale for and Design of a Global Registry. European Journal of Heart Failure. 17(5). 527–533. 46 indexed citations

Kothny, Wolfgang, Valentina Lukashevich, James E. Foley, Marc Rendell, & Anja Schweizer. (2015). Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial. Diabetologia. 58(9). 2020–2026. 24 indexed citations

10.

Åhrén, Bo, Chantal Mathieu, Giovanni Bader, Anja Schweizer, & James E. Foley. (2014). Efficacy of vildagliptin versus sulfonylureas as add-on therapy to metformin: comparison of results from randomised controlled and observational studies. Diabetologia. 57(7). 1304–1307. 37 indexed citations

11.

Bunck, Mathijs C., Elisabeth M. W. Eekhoff, Anja Schweizer, et al.. (2011). Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well‐controlled type 2 diabetes patients*. Journal of Diabetes. 4(2). 181–185. 53 indexed citations

12.

Åhrén, Bo, Anja Schweizer, S. Dejager, et al.. (2008). Vildagliptin improves alpha cell glucose sensing in patients with type 2 diabetes. Lund University Publications (Lund University). 6 indexed citations

13.

Schweizer, Anja, et al.. (2008). Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes (T2DM) and mild hyperglycemia. Diabetologie und Stoffwechsel. 3(S 1). 2 indexed citations

14.

Schweizer, Anja & Klaus Schröppel. (2008). Experimental Infection of Rodent Mammals for Fungal Virulence Testing. Methods in molecular biology. 470. 141–149. 1 indexed citations

15.

Dejager, S., et al.. (2007). Vildagliptin in Drug-naïve Patients with Type 2 Diabetes: A 24-Week, Double-blind, Randomized, Placebo-controlled, Multiple-dose Study. Hormone and Metabolic Research. 39(3). 218–223. 187 indexed citations

16.

Åhrén, Bo, Mona Landin‐Olsson, Per‐Anders Jansson, et al.. (2004). Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 89(5). 2078–2084. 607 indexed citations breakdown →

17.

Valdenaire, Olivier, J. G. Richards, Richard L. M. Faull, & Anja Schweizer. (1999). XCE, a new member of the endothelin-converting enzyme and neutral endopeptidase family, is preferentially expressed in the CNS. Molecular Brain Research. 64(2). 211–221. 73 indexed citations

18.

Turner, Anthony J., Kay Barnes, Anja Schweizer, & Olivier Valdenaire. (1998). Isoforms of endothelin-converting enzyme: why and where?. Trends in Pharmacological Sciences. 19(12). 483–486. 57 indexed citations

19.

Kanowski, S., et al.. (1995). Confirmed Clinical Efficacy of Actovegin^®in Elderly Patients with Organic Brain Syndrome. Pharmacopsychiatry. 28(4). 125–133. 24 indexed citations

20.

Schweizer, Anja, Maria Ericsson, Thomas Bächi, Gareth Griffiths, & Hans‐Peter Hauri. (1993). Characterization of a novel 63 kDa membrane protein : Implications for the organization of the ER-to-Golgi pathway. Journal of Cell Science. 104(3). 671–683. 132 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact